Richard Adler, MD, FACS, provides insights on data presented at AA0 2023, from a study comparing results of the ARMOR procedure versus treatment with cyclosporine ophthalmic emulsion 0.05% in patients with dry eye disease.
This is a video synopsis/summary of a Post Conference Perspectives featuring Richard Adler, MD.
Adler discusses results from the SAHARA trial evaluating an investigational procedure called Aqueous Retention and Meibomian Gland Outflow Restoration (ARMOR) for dry eye disease. The ARMOR procedure involves debridement, thermal compression, and expression of the meibomian glands in the eyelids to improve meibum quality and reduce tear evaporation.
The SAHARA trial compared ARMOR to Restasis (cyclosporine ophthalmic emulsion 0.05%) for improving tear breakup time (TBUT) and symptoms in evaporative dry eye. TBUT measures tear evaporation rate. The study found ARMOR showed clinically and statistically significant improvements in both TBUT and symptoms compared with Restasis over 12 weeks.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Gefurulimab for gMG Meets Key End Points in PREVAIL Trial
July 28th 2025The primary endpoint in PREVAIL is Myasthenia Gravis-Activities of Daily Living total score improvement from baseline, and the secondary endpoints are Quantitative Myasthenia Gravis total score and Myasthenia Gravis Composite total score.
Read More